Dr. Reddy’s Sees Weight-Loss Drug Boosting Growth After Setback

Dr. Reddy’s Laboratories Ltd. expects its generic anti-obesity drug to shore up growth in the six months through March after it resolves an impurity issue with the key ingredient and resumes supply in early November.

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.